A Safety and Efficacy Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced Malignant Solid Tumors
Latest Information Update: 08 Jan 2024
At a glance
- Drugs Anti CEA CAR T cell therapy-Chongqing Precision Biotech (Primary) ; Anti CEA CAR T cell therapy-Chongqing Precision Biotech (Primary) ; Cyclophosphamide; Fludarabine
- Indications Colorectal cancer; Gastric cancer; Oesophageal cancer; Pancreatic cancer; Solid tumours
- Focus Adverse reactions
- Sponsors Chongqing Precision Biotech Co., Ltd
Most Recent Events
- 12 Nov 2023 Planned End Date changed from 15 Sep 2024 to 15 Sep 2025.
- 12 Nov 2023 Planned primary completion date changed from 15 Sep 2023 to 15 Sep 2024.
- 15 Jun 2022 New trial record